Close

Solid Biosciences (SLDB) Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement

Go back to Solid Biosciences (SLDB) Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement

Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement

September 30, 2022 7:00 AM EDT

- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo -

- Strong synergies expected by combining key assets, including product candidates for Duchenne muscular dystrophy, Friedreichs ataxia, BAG3 mediated dilated cardiomyopathy and other undisclosed cardiac diseases, novel capsid libraries, and personnel -

- Combined company is expected to have approximately $215 million in cash and investments, which is expected to fund the combined company into 2025 and support attainment of key... More